Month: May 2020

NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today a lease agreement with the Tel Aviv Sourasky Medical Center (“Sourasky) in Tel Aviv, Israel, to produce NurOwn® in three state-of-the-art cleanrooms. The new facility will significantly increase the Company’s capacity to manufacture and ship its product into the European Union and the local Israeli market. The cleanroom facility is part of Sourasky’s Institute for Advanced Cellular Therapies.“Sourasky Hospital is a leader in the advancement and manufacturing of cell and gene therapy products and is well-equipped to rapidly scale up and produce NurOwn,” stated Prof. Ronni Gamzu, CEO of Tel Aviv Sourasky Medical...

MONT-SAINT-GUIBERT, Belgium, May 07, 2020 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on operational developments for the first quarter ended March 31, 2020.“I am extremely proud of our team’s dedication and focus over the past few months in progressing the development of our exciting CAR-T therapies during the COVID-19 pandemic. As a result of their efforts, we’ve continued to advance our programs, bringing us closer to several key milestones associated with our clinical and preclinical programs over the course of 2020. Specifically, we anticipate announcing additional data from our CYAD-101 alloSHRINK Phase 1 trial at ASCO, and filing the IND application for our lead shRNA-based...

 Limited business impact of COVID-19 crisis during Q1Unprecedented partnering deal signed for Phase 2 Lyme vaccine candidate2020 full-year financial guidance updated with improved EBITDASARS-CoV-2 vaccine development program for COVID-19 initiatedSolid financial results in Q1 2020, with limited COVID-19 impactProduct sales revenue of €32.7 million in Q1 2020, similar to Q1 2019 (€32.8 million)Total revenues of €35.2 million in Q1 2020, similar to Q1 2019 (€34.9 million)Gross margin on product sales revenues of 69.4% in Q1 2020 driven by geographical mix and strong operational performance in manufacturingEBITDA1 of €2.4 million in Q1 2020, lower than Q1 2019 (€8.2 million) due to increased R&D investmentsPositive operating cash flow of €3.0 million in Q1 2020Strong cash position of €80.8 million at the end of March 2020Supported by...

 Impact limité de la crise du COVID-19 au T1  Partenariat sans précédent signé pour le candidat vaccin de Phase 2 contre la maladie de LymeRévision des prévisions 2020 avec notamment une amélioration de l’EBITDAInitiation du développement d’un vaccin SARS-CoV-2 contre le COVID-19  Résultats financiers solides publiés au T1 2020, impact limité du COVID-19Ventes de produits de €32,7 millions au T1 2020, stables vs T1 2019 (€32,8 millions)Chiffre d’affaires total de €35,2 millions au T1 2020, stable vs T1 2019 (€34,9 millions)Marge brute sur les ventes de produits de 69,4% au T1 2020 soutenue par la multiplicité des zones géographiques et la solide performance opérationnelle des sites de production du GroupeEBITDA1 de €2,4 millions au T1 2020, inférieur à celui du T1 2019 (€8,2 millions) en raison d’une augmentation des investissements de...

Luxembourg, May 7, 2020 – ArcelorMittal (referred to as “ArcelorMittal” or the “Company”) (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s leading integrated steel and mining company, today announced results1 for the three-month period ended March 31, 2020.COVID-19 impacts Faced with a significant humanitarian challenge from the COVID-19 pandemic, the Company’s first priority has been to take all the necessary actions to safeguard the wellbeing of our people and to provide support to the extent required in the communities in which we operateEconomic activity and steel market conditions have significantly deteriorated since measures were introduced by governments worldwide to contain the COVID-19 pandemicThe Company has responded swiftly: aligning production to a lower order book, and taking measures to reduce...

First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC)Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLCKey highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CESTBasel, 7 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this...

In Q1 2020 Inbank earned a net profit of 2.2 million euros. Quarterly return on equity was 18%.Q1 net profit grew 8% compared to Q1 2019, when Inbank reported a net profit of 2.0 million euros.Inbank’s loan portfolio increased 40% compared to Q1 2019 reaching 345 million euros. At the same time, the deposit portfolio grew 34%, reaching 370 million euros at the end of Q1.Total sales for Q1 was 67 million euros, showing an increase of 15% compared to Q1 of the previous year. In terms of growth, the largest market continues to be Poland growing 86% year-on-year.By the end of Q1, the number of active contracts reached 600,000 and the number of active partners we are working with reached 2,900.Jan Andresoo, Chairman of the Management Board, comments on the results:“The first two and a half months of 2020 passed as forecasted – the business...

Inbanki 2020. aasta esimese kvartali puhaskasum oli 2,2 miljonit eurot. Omakapitali tootlus oli esimeses kvartalis 18%.2020. aasta esimese kvartali puhaskasum kasvas eelmise aasta sama perioodiga võrreldes 8% ehk 2,0 miljonilt eurolt 2,2 miljoni euroni.Inbanki laenuportfell kasvas 2019. aasta esimese kvartaliga võrreldes 40% ja ulatus 345 miljoni euroni. Hoiuseportfell kasvas aastaga 34% ja ulatus 2020. aasta esimese kvartali lõpus 370 miljoni euroni.Esimese kvartali müügimaht oli kokku 67 miljonit eurot. Eelmise aasta esimese kvartaliga võrreldes kasvas see 15%. Riikide arvestuses on Inbanki suurima kasvuga turg endiselt Poola, kus müügimahud suurenesid mullusega võrreldes 86%.Kvartali lõpus oli Inbankil 600 000 aktiivset kliendilepingut ja 2900 koostööpartnerit.Tulemusi kommenteerib Inbanki juhatuse esimees Jan Andresoo:„2020. aasta...

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2020. Please also see announcement dated 23 April 2020.Dividend amount: 0.09Declared currency: USDLast day including rights: 13 August 2020Ex-date: 14 August 2020Record date: 17 August 2020Payment date: 28 August 2020Other information: Dividend per share in NOK will be communicated 21 August 2020.This information is published in accordance with the requirements of the Continuing Obligations.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Nøkkelinformasjon vedrørende kontantutbytte for Equinor (OSE: EQNR, NYSE: EQNR) for første kvartal 2020. Se også børsmelding datert 23. april 2020.Utbyttebeløp: 0,09Annonsert valuta: USDSiste dag inklusive: 13. august 2020Ex-dato: 14. august 2020Record date (eierregisterdato): 17. august 2020Betalingsdato: 28. august 2020Øvrig informasjon: Utbytte i NOK per aksje vil bli kommunisert 21. august 2020.Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser.Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12